Our Trials

Clinical Trials for VAL-083

VAL-083 is a structurally unique, "first-in-class", small-molecule chemotherapeutic. Based on historical data and our own research, we believe that VAL-083 has the potential to offer physicians and patients a new paradigm in the treatment of Glioblastoma Multiforme (GBM).

The purpose of this Phase 2, open-label, single-arm study is to determine the safety and the

For Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression: More Information

The purpose of this Phase 1/2, open-label, single-arm study is to determine the safety and

For Patients With Recurrent Malignant Glioma: More Information

Requests for Expanded Access

This Policy for Requests for Expanded Access to Investigational Drugs describes the principles and procedures that Kintara Therapeutics, Inc. will follow when considering requests by licensed physicians for use of Kintara’s investigational drugs outside of clinical trials.

View Policy

Enrollment

For more information on enrollment into the current VAL-083 trial, please contact us or visit clinicaltrials.gov for location information.

The safety and efficacy of the investigational use of this product has not been determined. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by a regulatory agency.